about
A Perspective of Immunotherapy for Prostate CancerMelatonin as a potential anticarcinogen for non-small-cell lung cancerChimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and ProspectsMelanoma: oncogenic drivers and the immune systemEngineering opportunities in cancer immunotherapyRelevance of tumor-infiltrating lymphocytes in breast cancerPerspectives in the treatment of pancreatic adenocarcinomaCAR T cells for solid tumors: armed and ready to go?Pathways and therapeutic targets in melanomaAdoptive T-cell therapy for LeukemiaGene therapy on the moveTh17 Cell Plasticity and Functions in Cancer ImmunityImmunotargeting of cancer stem cellsHarnessing immunosurveillance: current developments and future directions in cancer immunotherapyTrial watch: Dendritic cell-based anticancer therapyCancer vaccinesGenetically modified T cells in cancer therapy: opportunities and challengesAntigen-specific T cells fully conserve antitumour function following cryopreservation.High-content molecular profiling of T-cell therapy in oncologyImmunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor siteThe Intercellular Metabolic Interplay between Tumor and Immune CellsInhibition of G-protein βγ signaling enhances T cell receptor-stimulated interleukin 2 transcription in CD4+ T helper cellsA 3D microfluidic model for preclinical evaluation of TCR-engineered T cells against solid tumors.5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells.Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.Masked Chimeric Antigen Receptor for Tumor-Specific Activation.Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.Improving the safety of cell therapy with the TK-suicide geneAgonist antibody that induces human malignant cells to kill one another.Clinical application of genetically modified T cells in cancer therapy.Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacyAdoptive T cell immunotherapy for cancer.Classification of current anticancer immunotherapiesIn vivo antitumor and antimetastatic effects of flavokawain B in 4T1 breast cancer cell-challenged mice.Classifying Cancers Based on T-cell Infiltration and PD-L1.Evaluating Human T-Cell Therapy of Cytomegalovirus Organ Disease in HLA-Transgenic Mice.Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor ActivityLYRA, a webserver for lymphocyte receptor structural modelingPolyethyleneimine-modified calcium carbonate nanoparticles for p53 gene deliveryTranspo-mAb display: Transposition-mediated B cell display and functional screening of full-length IgG antibody libraries.
P2860
Q26741277-B08067C1-1434-4C83-A30F-8D41CBA0A4BEQ26751220-EA624A78-2803-4E8D-A875-826BC8C68C5AQ26753082-43AA1680-4306-459C-96EC-94A95FAD5E23Q26775598-5461FB11-A05F-4FCD-9C87-4719F406253DQ26776373-FCBF62C1-1B25-47B7-AA65-BBC2C3AE8C2DQ26795598-030F63B9-ED03-4137-9F9D-8F34FBE7C328Q26797248-3E60BD09-0B8D-45F4-A36C-0163E5CA7980Q26825489-80AC3D59-E36E-4E94-995F-7750FF492935Q26865736-139DF60D-5E7D-45B8-AA41-96B594913DBCQ27006934-CD0106B0-8C5C-4626-B705-C17AFEA0A01CQ27007012-A8B28E91-50E9-454A-938A-6FF2F8528532Q27012901-3F1473DB-BEAE-4F83-B061-D1D29B3C7302Q27014031-A6B0064F-36B9-4904-ACAE-52F852B58FEEQ27021570-0350BF1D-157B-4EC9-996A-F6FE701D54CDQ27024047-732CCA8D-40C2-4290-AA47-FD121CE65780Q27024438-BED78F45-1D9A-4585-9D56-88F428833639Q27026627-CEF0BF28-5F47-4C9B-A5CC-9CBD4A28D21FQ27323082-50B48AB1-72B3-48FB-B98E-A4388025CD91Q28066792-3019860D-539B-4F64-A3E1-5E1EB7A4ADAFQ28066935-FCE36038-D0B7-47C0-A4E0-3E93D1A41036Q28391079-4A680D0C-1CF9-462B-808E-60C159E08FB4Q28543127-9B823228-DFCE-4FCD-A757-021C8491C1B2Q33803754-89954DBB-3804-4829-B408-5D60BE158A70Q33884816-BA8BFB20-410F-4C77-85F7-C7F204EEA88EQ34041792-2F6A03FB-D405-44F8-9C62-3B14BBA24538Q34047878-78730F1E-20A8-4DB0-B3D8-DFA888CC80E6Q34431441-10B44116-3896-48D0-B108-8715BEAED37AQ34477411-3ABFD800-4FE6-4EB9-A95B-7D1489C83872Q34498809-2B01529C-9248-4E7E-BAF2-6F51F4010EDDQ34511646-C587BBDA-59A3-440E-9516-2F0D2289615BQ34550649-0B48B12B-B4E6-4C15-B59B-0E627D8AF98AQ35081485-1920A843-66D6-40CF-A11C-DE21411D82D8Q35149637-5F817608-CE20-41C9-984B-4232AF79C088Q35174206-08705956-1BC1-4040-907E-C4080205EEBCQ35674821-585BE534-B17A-410A-B245-7D45CDF63276Q35693349-5861BBAB-D22E-4DC0-B191-F626CE06930AQ35745453-22EF2F30-A64A-45B0-B2B3-51B5165CC90BQ35810098-73F30CE3-0350-4965-B289-77043A21A261Q35905841-5128A891-5351-4961-9CB4-919C9D36FB9DQ35961115-018C7E8B-0815-4B35-BA8B-BFAE6D01F58B
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Gene-engineered T cells for cancer therapy.
@en
type
label
Gene-engineered T cells for cancer therapy.
@en
prefLabel
Gene-engineered T cells for cancer therapy.
@en
P2093
P356
P1476
Gene-engineered T cells for cancer therapy.
@en
P2093
Jennifer A Westwood
Michael H Kershaw
Phillip K Darcy
P2888
P304
P356
10.1038/NRC3565
P407
P577
2013-08-01T00:00:00Z
P6179
1027453640